Selected article for: "acute infection and IFNs type"
Author: Kim, You-Me; Shin, Eui-Cheol
Title: Type I and III interferon responses in SARS-CoV-2 infection
  • Cord-id: hh5zaa9i
  • Document date: 2021_5_6
    • ID: hh5zaa9i
    Snippet: Coronavirus disease 2019 (COVID-19), the current pandemic disease, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Type I and III interferons (IFNs) are innate cytokines that are important in the first-line defense against viruses. Similar to many other viruses, SARS-CoV-2 has evolved mechanisms for evading the antiviral effects of type I and III IFNs at multiple levels, including the induction of IFN expression and cellular responses to IFNs. In this review,
    Document: Coronavirus disease 2019 (COVID-19), the current pandemic disease, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Type I and III interferons (IFNs) are innate cytokines that are important in the first-line defense against viruses. Similar to many other viruses, SARS-CoV-2 has evolved mechanisms for evading the antiviral effects of type I and III IFNs at multiple levels, including the induction of IFN expression and cellular responses to IFNs. In this review, we describe the innate sensing mechanisms of SARS-CoV-2 and the mechanisms used by SARS-CoV-2 to evade type I and III IFN responses. We also discuss contradictory reports regarding impaired and robust type I IFN responses in patients with severe COVID-19. Finally, we discuss how delayed but exaggerated type I IFN responses can exacerbate inflammation and contribute to the severe progression of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activate rig and long length: 1
    • activation accumulation and acute respiratory syndrome: 1, 2, 3, 4
    • activation accumulation and lung tissue: 1, 2, 3
    • activation rig ubiquitination and acute respiratory syndrome: 1, 2, 3
    • acute phase and long length: 1
    • acute phase and longitudinal analysis: 1, 2, 3, 4
    • acute phase and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory syndrome and additional expression: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and long length: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and long variant: 1
    • acute respiratory syndrome and longitudinal analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • long variant and lung pathology: 1